Clinical trials: PARP Inhibitor
Biliary Tract Cancer
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Investigators hypothesize that following first-line platinum based chemotherapy, rucaparib in combination with nivolumab, will improve progression-free survival and overall survival in BTC patients.
- Trial name
- NCT03639935
- Testing
- Rucaparib, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Squamous Cell Carcinoma
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Multi-center, open-label, non-randomized, non-comparative two-cohort study for patients with locally-advanced squamous cell carcinoma arising from the larynx, hypopharynx, oropharynx (Stage III, IVA and IVB according to 8th…
- Trial name
- RADIAN (NCT05784012)
- Testing
- Dostarlimab, Niraparib, cisplatin plus radiotherapy
- Where
- 7 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Ovarian Cancer, Recurrent Ovarian Carcinoma
A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results
In ovarian cancer (OC), complete surgical debulking and platinum-based chemotherapy are the standard treatment, now followed by maintenance therapy with PARP inhibitors or Bevacizumab.
- Trial name
- FOFU (NCT06541171)
- Testing
- Magnetic resonance imaging as fpr clinical practice
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Melanoma
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene…
- Trial name
- NCT05983237
- Testing
- Fluzoparib Camrelizumab Temozolomide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jun Guo
Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy.
- Conditions
- Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin, Paclitaxel
- Trial name
- NCT00516724
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor), Carboplatin, Paclitaxel
- Where
- 4 sites in Belgium, Netherlands and 1 more
- Volunteers
- 189 people
- Sponsor
- AstraZeneca
Urothelial Carcinoma, Urothelial Cancer
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
Background: EP0057 (formerly CRLX101) consists of a sugar molecule cyclodextrin linked to a chemotherapy drug called camptothecin. The combined molecule or "nanoparticle drug conjugate" travels through the blood.
- Conditions
- Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms, Small Cell Lung Cancer
- Trial name
- NCT02769962
- Testing
- EP0057, olaparib, CT scan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Breast, Carcinoma of Breast
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
The purpose of this study is to compare progression-free survival (PFS) in patients with advanced/metastatic breast cancer who have a BRCA mutation when treated with niraparib as compared to those treated with physician's choice
- Conditions
- Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, BRCA1 Gene Mutation
- Trial name
- BRAVO (NCT01905592)
- Testing
- niraparib, Physician's choice
- Where
- 104 sites in United States, Belgium and 12 more
- Volunteers
- 216 people
- Sponsor
- Tesaro, Inc.
Ovarian Cancer
Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
JAVELIN Ovarian PARP 100 (B9991030) is an open-label, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with…
- Trial name
- NCT03642132
- Testing
- Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
- Where
- 72 sites in United States, Australia and 8 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Ovarian Cancer
Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
Poly(ADP-ribose) polymerase (PARP) inhibitors are anti-cancer treatments that induce preferential tumor cell death. Their efficacy has been demonstrated in many tumor models, primarily in advanced ovarian cancer.
- Trial name
- PARIB-OLD-PRO² (NCT06572735)
- Testing
- QoL surveys, Geriatric assessment (G-CODE), Blood sampling
- Where
- 16 sites in France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Ovarian Cancer
BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Background: The new drug BMN 673 (talazoparib) has been shown to fight tumor cells in animals and some people. It is a poly (ADP-ribose) polymerase (PARP) inhibitor.
- Trial name
- NCT02326844
- Testing
- BMN 673 (talazoparib)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms, Breast Neoplasms
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Background: Durvalumab is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells.
- Trial name
- NCT02484404
- Testing
- Olaparib, Cediranib, Durvalumab
- Where
- United States
- Volunteers
- 268 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Breast Cancer
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CYH33 in combination with olaprib in patients with DDR gene mutations and/or PIK3CA mutations, in patients who have progressed on prior…
- Conditions
- Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer
- Trial name
- NCT04586335
- Testing
- CYH33
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Metastatic Breast Cancer
Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
2X-121 is a small molecule targeted inhibitor of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells.
- Trial name
- NCT03562832
- Testing
- PARP inhibitor 2X-121
- Where
- 2 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Allarity Therapeutics
Breast Cancer, Triple Negative Breast Cancer
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer.
- Trial name
- NADiR (NCT04837209)
- Testing
- Niraparib, Dostarlimab, Radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Ewing Sarcoma
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with…
- Trial name
- NCT02044120
- Testing
- niraparib, Temozolomide, Irinotecan
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 34 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with floxuridine in treating patients with epithelial ovarian, primary peritoneal cavity, or fallopian tube cancer that has spread to…
- Conditions
- Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Trial name
- NCT01749397
- Testing
- Floxuridine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, PARP Inhibitor
PARPi and Ovarian Cancer Survival
With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent…
- Trial name
- NCT06838429
- Volunteers
- 6,000 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Pancreatic Acinar Cell Carcinoma
Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma
Background: Pancreatic Acinar Cell Carcinoma (PACC) is a rare pancreatic tumor. People with PACC usually present with advanced disease, and their prognosis is poor.
- Trial name
- NCT05286827
- Testing
- Olaparib, ECG, CT CAP
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and…
- Trial name
- NCT05257993
- Testing
- JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
- Where
- 4 sites in South Korea
- Volunteers
- 71 people
- Sponsor
- Onconic Therapeutics Inc.